Marker Therapeutics, Inc.
MRKR Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.91
KIRA · Stoqly’s AI analyst, in plain words
- Marker Therapeutics, Inc. had $3.5M of revenue in fiscal 2025, down 46.2% on the year before. Over five years, revenue changed +48.0% a year on average.
- Its operating margin was −363.4%, down 194.8 pts: of every 100 in sales, about −363 is left after running the business.
- Marker Therapeutics, Inc. lost $12.2M in fiscal 2025.
Market cap
$17.5M
P/E
—
Revenue
$3.5M
Net income
−$12.2M
Free cash flow
—
Operating margin
−363.4%
Marker Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−46.2%
No. Sales fell 46.2% last year.
Does it make a profit?
−343.0%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Marker Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- Marker Therapeutics, Inc.
- CIK
- 0001094038
Marker Therapeutics, Inc. · MRKR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $3.5M | $3.3M | $6.6M | $3.5M |
| Revenue growth | −100.0% | — | −5.8% | 99.1% | −46.2% |
| Operating margin | — | −563.3% | −440.4% | −168.7% | −363.4% |
| Net income | −$41.9M | −$29.9M | −$8.2M | −$10.7M | −$12.2M |
| Net margin | — | −851.9% | −248.8% | −162.8% | −343.0% |
| Diluted EPS | −$5.47 | −$3.58 | −$0.94 | −$1.19 | −$0.79 |
| Cash | |||||
| Cash from operations | −$27.3M | −$27.0M | −$16.4M | −$10.9M | −$12.0M |
| Share count change | −83.7% | 9.2% | 5.5% | 1.9% | 70.5% |
| Debt and strength | |||||
| Cash and short-term investments | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Shareholders' equity | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
| Current ratio | 3.6x | 2.1x | 5.6x | 6.4x | 8.4x |
| Returns and quality | |||||
| Return on equity | −117.4% | −94.1% | −49.0% | −65.8% | −68.8% |
| Return on tangible equity | −95.2% | −152.7% | −58.6% | −57.8% | −72.4% |
| Piotroski F-score | 3 | 2 | 3 | 2 | 2 |
| Altman Z'' | −17.8 | −41.3 | −78.6 | −58.4 | −69.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Marker Therapeutics, Inc. · MRKR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.91 a share, the company is worth $17.5M.
Source: SEC EDGAR XBRL filings (CIK 0001094038). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.